Cargando…
Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum
BACKGROUND: The increased resistance of the human malaria parasite Plasmodium falciparum to currently employed drugs creates an urgent call for novel anti-malarial drugs. Particularly, efforts should be devoted to developing fast-acting anti-malarial compounds in case clinical resistance increases t...
Autores principales: | Duffey, Maëlle, Sanchez, Cecilia P., Lanzer, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861637/ https://www.ncbi.nlm.nih.gov/pubmed/29558913 http://dx.doi.org/10.1186/s12936-018-2279-4 |
Ejemplares similares
-
SC83288 is a clinical development candidate for the treatment of severe malaria
por: Pegoraro, Stefano, et al.
Publicado: (2017) -
Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria
por: Pegoraro, Stefano, et al.
Publicado: (2017) -
Knockout of the peroxiredoxin 5 homologue PFAOP does not affect the artemisinin susceptibility of Plasmodium falciparum
por: Djuika, Carine F., et al.
Publicado: (2017) -
In vitro interaction of artemisinin derivatives or the fully synthetic peroxidic anti-malarial OZ277 with thapsigargin in Plasmodium falciparum strains
por: Abiodun, Oyindamola O, et al.
Publicado: (2013) -
Anti-malarial drugs: how effective are they against Plasmodium falciparum gametocytes?
por: Peatey, Christopher L, et al.
Publicado: (2012)